{"doc_id": "med:pmid:33119090", "sentence_id": "med:pmid:33119090:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34632983", "sentence_id": "med:pmid:34632983:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This was a retrospective, observational, single-centre, hypothesis-generating study of patients with symptomatic heart failure and reduced ejection fraction (HFrEF) treated with guideline recommended therapy, who were transitioned from an ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) to sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34969175", "sentence_id": "med:pmid:34969175:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34969175", "sentence_id": "med:pmid:34969175:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p\u00a0=\u00a00.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p\u00a0=\u00a00.025).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34986674", "sentence_id": "med:pmid:34986674:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The patient's heart function greatly improved after changing this ACEI to sacubitril/valsartan.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34986674", "sentence_id": "med:pmid:34986674:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Changing an ACEI/ARB to sacubitril/valsartan in patients with worsening chemotherapy-induced heart failure is appropriate.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with heart failure, sacubitril/valsartan reduced the risk of serious adverse renal outcomes and slowed decline in eGFR, compared with valsartan or enalapril, independent of baseline renal function.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The composite renal outcome occurred in 70 of 6594 patients (1.1%) in the sacubitril/valsartan group and in 123 of 6601 patients (1.9%) in the valsartan or enalapril group (hazard ratio 0.56, 95% confidence interval [CI] 0.42-0.75; p\u2009<\u20090.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34989105", "sentence_id": "med:pmid:34989105:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean eGFR change was -1.8 (95% CI -1.9 to -1.7) ml/min/1.73 m<sup>2</sup> /year for the sacubitril/valsartan group, compared with -2.4 (95% CI -2.5 to -2.2) ml/min/1.73 m<sup>2</sup> /year for the valsartan or enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:34994233", "sentence_id": "med:pmid:34994233:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35022763", "sentence_id": "med:pmid:35022763:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35022763", "sentence_id": "med:pmid:35022763:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35035857", "sentence_id": "med:pmid:35035857:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Studies have shown sacubitril/valsartan can further reduce the risk of cardiovascular death or hospitalization for heart failure by 20% compared with enalapril.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35081164", "sentence_id": "med:pmid:35081164:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan was similar to either enalapril or valsartan in preventing the occurrence of AF in patients with HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35081164", "sentence_id": "med:pmid:35081164:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no significant difference in the prevention of AF occurrence between the sacubitril/valsartan group and the control group (enalapril or valsartan) in patients with HF (RR 1.07, 95%CI 0.95 to 1.19; I2 4%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35094306", "sentence_id": "med:pmid:35094306:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study compared real-world outcomes of ARNI (SAC/VAL) vs. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy in RAASi-na\u00efve patients with HF and reduced ejection fraction (HFrEF).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35097007", "sentence_id": "med:pmid:35097007:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacies of 13 intervention classes, including monotherapies or combinations of ACEI, ARB, ARNI, BB, MRA, SGLT2i, IVA, and placebo, on hospitalization for HF, cardiovascular mortality, and all-cause mortality were compared.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35097007", "sentence_id": "med:pmid:35097007:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among the 13 included interventions, ARNI+BB+MRA, SGLT2i+ACEI+BB+MRA, and IVA+ACEI+BB+MRA were found to be best in terms of all three outcomes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35200707", "sentence_id": "med:pmid:35200707:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the PARADIGM-HF study in 2014.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35222898", "sentence_id": "med:pmid:35222898:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35253964", "sentence_id": "med:pmid:35253964:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients received sacubitril/valsartan \u00a0200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35257446", "sentence_id": "med:pmid:35257446:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients receiving both an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/ARNi and a \u03b2-blocker at 50%-99% of TD had a lower adjusted risk of the primary outcome compared with patients only receiving one drug, i.e. ACEi/ARB/ARNi or \u03b2-blocker, even if this was at \u2265100% of TD.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35260016", "sentence_id": "med:pmid:35260016:sec:introduction:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In some cases, the ARNI sacubitril/valsartan may be initiated even in ACE inhibitor-na\u00efve patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35268260", "sentence_id": "med:pmid:35268260:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incidence of outpatient HF or HF hospitalization in the ARNI group was significantly lower than that in the enalapril group (HR, 0.36; 95% CI: 0.14 to 0.94; P=0.037).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We found that NT-proBNP concentration decreased more in the ARNI group than in the enalapril group [4 weeks: ratio of ARNI <i>vs.</i> enalapril 0.36, 95% confidence interval (CI): 0.24 to 0.52, P<0.001; 12 weeks: 0.54, 95% CI: 0.35 to 0.79, P<0.001; 24 weeks: 0.53, 95% CI: 0.32 to 0.83, P<0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35282662", "sentence_id": "med:pmid:35282662:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "When compared to the enalapril group, the ARNI group patients had a significant reduction in LVEDV (P<0.001) and LVESV (P<0.001), and an improvement in LVEF (P=0.011) at 24 weeks.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35332595", "sentence_id": "med:pmid:35332595:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In a sensitivity analysis considering the ARNI and non-ARNI subgroups of SGLT2i RCTs, the combination SGLT2i\u00a0+\u00a0ARNI\u00a0+\u00a0BB\u00a0+\u00a0MRA was associated with the lowest HR (0.28, 95% CrI 0.16-0.45 vs. 0.40, 95% CrI 0.24-0.60 for SGLT2i\u00a0+\u00a0BB\u00a0+\u00a0ACEi\u00a0+\u00a0MRA).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35343504", "sentence_id": "med:pmid:35343504:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADIGM-HF trial demonstrated a favorable effect of sacubitril/valsartan over enalapril in terms of mortality and heart failure hospitalization rate reduction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEIs or ARBs, ARNIs were associated with comparable clinical and renal outcomes in patients with HFrEF and advanced CKD (eGFR \u2264 30 mL/min/1.73 m<sup>2</sup>).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients who had never been prescribed with an ARNI, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB) were excluded.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There were 206 patients in the ARNI group and 833 patients in the ACEI/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After IPTW adjustment, the mean ages (65.1 vs. 66.6 years), male patients (68.3 vs. 67.9%), left ventricular ejection fraction (30.5 vs.31.2%), eGFR (20.9 vs. 20.3 mL/min/1.73 m<sup>2</sup>) were comparable in the ARNI and ACEI/ARB groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After IPTW adjustment, the mean follow-up durations were 7.3 months and 6.6 months in the ARNI and ACEI/ARB groups, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35360037", "sentence_id": "med:pmid:35360037:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI and ACEI/ARB users had a comparable risk of the composite clinical event (all-cause mortality or heart failure hospitalization) (hazard ratio [HR], 1.31; 95% confidence interval (CI) 0.91-1.88) and progression to dialysis (HR 1.04; 95% CI 0.54-2.03).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35365031", "sentence_id": "med:pmid:35365031:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The experimental group was given Sacubitril/Valsartan sodium tablets, while the control group was given angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35392695", "sentence_id": "med:pmid:35392695:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Background:</b> Heart failure guidelines recommend replacing an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) with an angiotensin receptor neprilysin inhibitor (ARNI) to reduce morbidity and mortality in NYHA Class II-III patients with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35400328", "sentence_id": "med:pmid:35400328:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan has revealed superior glycemic and blood pressure control compared with enalapril and irbesartan in patients with heart failure and type 2 diabetes and in individuals with chronic kidney disease.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35404555", "sentence_id": "med:pmid:35404555:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Key search terms were ADEs for \u03b2-blockers (BBs), ACE inhibitors (ACEis), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and/or angiotensin receptor-neprilysin inhibitors (ARNis) in adult patients (\u2265\u200918 years) with\u00a0HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35418252", "sentence_id": "med:pmid:35418252:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A combination of MeSH terms of \"cost-effectiveness analysis,\" \"heart failure with reduced ejection fraction,\" \"sacubitril valsartan,\" and \"angiotensin converting enzyme inhibitor\" was employed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35469709", "sentence_id": "med:pmid:35469709:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enalapril on the reduction of cardiovascular (CV) mortality and heart failure hospitalizations rates.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The ARNI study group showed better safety and efficacy outcomes at the end of 6 months follow-up compared to ACEI group.", "sentiment_label": "POS", "sentiment_score": 3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To compare the safety and efficacy of valsartan/sacubitril (angiotensin receptor neprilysin inhibitor [ARNI]) against enalapril (angiotensin-converting enzyme inhibitor [ACEI]) in patients with acute heart failure at 6-month follow-up.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were divided in two groups: valsartan/sacubitril (ARNI) group and enalapril (ACEI).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Readmission for heart failure were seen significantly higher in ACEI group than ARNI group (p value\u00a0=\u00a00.001).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 200 patients were included in the present study, 100 each in ARNI and ACEI group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean age of the population was 61.2\u00a0\u00b1\u00a08.4 years and 62.6\u00a0\u00b1\u00a08.6 years in ARNI group and ACEI group, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean maximum tolerated dose by population in ARNI group was 203.6\u00a0mg and 8.9\u00a0mg in ACEI group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35483448", "sentence_id": "med:pmid:35483448:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure - A prospective observational study.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35501544", "sentence_id": "med:pmid:35501544:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Secondary endpoints included\u00a0achieving target and/or maximally tolerated ACEI/ARB/ARNI and beta-blockers combined and individually as well as SGLT2i and AA GDMT at 90-day post-enrollment compared to baseline.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In clinical trials, sacubitril/valsartan has demonstrated significant survival benefits compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARB).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.484658+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Using a cohort of Medicare beneficiaries hospitalized with HFrEF between 2016 and 2018, we determined all-cause mortality and HF-readmission rates among patients not given ACEi/ARB or sacubitril/valsartan at hospital discharge, by age.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We then used risk reductions from the SOLVD, PARADIGM-HF and PIONEER-HF trials to estimate the benefits of ACEi/ARB and sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A Markov decision process model was used to simulate 5-year survival and estimate number needed to treat, comparing discharge on ACEi/ARB vs sacubitril/valsartan by age.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After accounting for drug discontinuation rates, which were surprisingly slightly higher among those discharged on ACEi/ARB (2.3%/month vs 1.9%/month), there was a small but significant survival advantage to discharge on sacubitril/valsartan over 5 years (+0.81 months [95% CI 0.80, 0.81]).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The benefit of sacubitril/valsartan over ACEi/ARB did not decrease with increasing age - the number needed to treat among 66 to 74-year-old patients was 84 and among 85+ year-old patients was 67.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35525261", "sentence_id": "med:pmid:35525261:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35546745", "sentence_id": "med:pmid:35546745:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The patients taking ACE inhibitors and mTOR inhibitors, DPP4 inhibitors, alteplase, or sacubitril/valsartan concurrently may be at increased risk of developing angioedema.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35560696", "sentence_id": "med:pmid:35560696:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the EVALUATE-HF trial (n\u00a0=\u00a0464) were randomized to sacubitril/valsartan or enalapril for 12\u2009weeks, followed by 12-week open-label sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35621872", "sentence_id": "med:pmid:35621872:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Currently, the ESC guidelines from 2021 indicate that ACEI, ARNI, BB, and SGLT2 inhibitors are the first-line drugs in HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35689603", "sentence_id": "med:pmid:35689603:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 27\u2009063 new sacubitril/valsartan users, most (n\u00a0=\u00a017\u2009663, 65%) were prescribed low-dose at 24\u2009mg/26\u2009mg and most (n\u00a0=\u00a019\u2009984, 74%) were switched from prior angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) rather than being RASi treatment na\u00efve.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35690600", "sentence_id": "med:pmid:35690600:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We compared the HbA<sub>1c</sub> level reduction between the ARNI and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in chronic heart failure patients with diabetes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35690600", "sentence_id": "med:pmid:35690600:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over the study period, ARNI did not significantly lower the HbA<sub>1c</sub> level after adjusting confounding factors compared to ACEIs or ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35690600", "sentence_id": "med:pmid:35690600:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, as a result of a simple comparison using Mann-Whitney U test, ARNI group showed significant decrease in HbA<sub>1c</sub> at 6, 12, and 24\u00a0months compared to ACEIs or ARBs group (p\u2009=\u20090.003, 0.009, and 0.026, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35702942", "sentence_id": "med:pmid:35702942:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all-cause mortality in patients with ambulatory heart failure and reduced ejection fraction (HFrEF), in particular when it is maximally up-titrated.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35709921", "sentence_id": "med:pmid:35709921:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The increase of urine protein class in the ACEI/ARB group increased the risk of WRF with statistical significance (OR\u00a0=\u00a02.36, 95%CI 1.01-5.49, p\u00a0=\u00a00.047), but no statistical significance was found in all the patients or Sacubitril/Valsartan group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35709921", "sentence_id": "med:pmid:35709921:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, Sacubitril/Valsartan could more effectively slow down renal function decline and reverse myocardial remodeling in patients with CKD and HFpEF than ACEI/ARB, even at low doses, though its protective effect on urinary protein is not as good as that of ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35709921", "sentence_id": "med:pmid:35709921:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The outcome of proteinuria in the ACEI/ARB group was significantly better than that in the Sacubitril/Valsartan group (p\u00a0=\u00a00.001).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35709921", "sentence_id": "med:pmid:35709921:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In terms of echocardiogram, the average left atrial width in Sacubitril/Valsartan group decreased by 1.38\u00a0\u00b1\u00a03.02\u00a0mm, which was significantly lower than that in the ACEI/ARB group (p\u00a0=\u00a00.02).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35712811", "sentence_id": "med:pmid:35712811:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Our aim is to assess whether ARNi use may prevent deterioration in ejection fraction (EF) or is associated with EF improvement compared with ACEi in DMD patients with heart failure and to report the tolerability of ARNi in this group of patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35712811", "sentence_id": "med:pmid:35712811:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The first group received ARNi on top of BB, while the control group started or continued first-line therapy with ACEi\u00a0\u00b1\u00a0BB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35717169", "sentence_id": "med:pmid:35717169:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35717169", "sentence_id": "med:pmid:35717169:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Across the spectrum of LVEF, sacubitril/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63-0.89, P\u2009=\u20090.001), compared with enalapril or valsartan.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35736368", "sentence_id": "med:pmid:35736368:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARADISE-MI study compared standard treatment with an ACE inhibitor (ramipril) after an acute myocardial infarction with the newer sacubitril/ valsartan combination (so-called ARNI) medication in 5661 patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35736368", "sentence_id": "med:pmid:35736368:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study is characterized by an increased incidence of symptomatic hypotension of 28,3% in the group treated with the ARNI, compared to an incidence of 21,9% in the group treated with the ACE inhibitor.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35761118", "sentence_id": "med:pmid:35761118:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Frail patients in randomised trials of sacubitril/valsartan, aliskiren, or enalapril had twice the risk of mortality (hazard ratio [HR] 2.09, 1.62-2.71) and hospitalisations (HR 1.82, 1.37-2.41) compared with robust patients, which may reflect responsiveness to medications and/or factors unrelated to medication use.", "sentiment_label": "NEU", "sentiment_score": -0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35859597", "sentence_id": "med:pmid:35859597:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Background and objective</h4> Relevant data of PARADIGM-HF reveals sacubitril/valsartan (SV) therapy led to a greater reduction in the risks of arrhythmia, and sudden cardiac death than angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor inhibitor (ARB) therapy in HFrEF, however, inconsistent results were reported in subsequent studies.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35874853", "sentence_id": "med:pmid:35874853:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all <i>p</i>\u2009<\u20090.05): LVEF (47.07\u2009\u00b1\u20096.93% vs. 43.47\u2009\u00b1\u20097.95%); TAPSE (15.33\u2009\u00b1\u20091.31\u00a0vs. 14.78\u2009\u00b1\u20091.36\u2009mm); sPAP (36.76\u2009\u00b1\u200914.32\u00a0vs. 42.26\u2009\u00b1\u200912.07\u2009mmHg); and TAPSE/sPAP ratio (0.50\u2009\u00b1\u20090.23 vs. 0.39\u2009\u00b1\u20090.14), respectively.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35874853", "sentence_id": "med:pmid:35874853:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The comparative effects of sacubitril/valsartan versus\u00a0enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35902033", "sentence_id": "med:pmid:35902033:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In models accounting for the role of an HF clinic in initiation of these medications, being seen in an HF clinic was independently associated with initiation of new GDMT across all medication classes, with a hazard ratio (95% CI) of 1.54 (1.15-2.06) for any beta-blocker, 2.49 (1.95-3.20) for HF beta-blockers, 1.97 (1.46-2.65) for ACEis/ARBs/ARNIs, and 2.14 (1.49-3.08) for MRAs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35902033", "sentence_id": "med:pmid:35902033:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Most eligible patients received beta-blockers (92.6%) and ACEis/ARBs/ARNIs (87.0%) in the first year.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35990952", "sentence_id": "med:pmid:35990952:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEI/ARB, sacubitril/valsartan was more effective.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35990952", "sentence_id": "med:pmid:35990952:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Meta-analysis results showed that, in terms of the primary outcome, the sacubitril/valsartan group was superior than the ACEI/ARB group in improving HRQoL of HFrEF, and the difference was statistically significant (SMD 1.26; 95% CI: 0.14, 2.37; <i>p</i> = 0.03), while there was no significant difference between the two groups in HFpEF (SMD 0.37; 95% CI: -0.35, 1.09; <i>p</i> = 0.32).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35990986", "sentence_id": "med:pmid:35990986:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We compared the risk of AF recurrence in patients with catheter ablation who received ARNI with the risk of AF recurrence in those who received the angiotensin-converting enzyme inhibitor (ACEI).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35990986", "sentence_id": "med:pmid:35990986:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 679 eligible patients, 155 patients with ARNI treatment and 155 patients with ACEI treatment were included in the analyses.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35990986", "sentence_id": "med:pmid:35990986:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At a median follow-up of 228 (196-322) days, ARNI as compared with ACEI was associated with a lower risk of AF recurrence [adjusted hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.24-0.63; <i>p</i> < 0.001].", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:35999128", "sentence_id": "med:pmid:35999128:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of the 1,698 patients identified, ACEi/ARB/ARNI, beta blockers and MRA were dispensed in 80.2%, 83.6% and 45.4%, respectively, prior to ICD implant.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36016688", "sentence_id": "med:pmid:36016688:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The obs group was treated with Entresto, while the other with angiotensin-converting enzyme inhibitors (ACEI).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36125061", "sentence_id": "med:pmid:36125061:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>BACKGROUND:</b> Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36125061", "sentence_id": "med:pmid:36125061:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients receiving ARNIs were younger (aged 62 vs 69 years) and had a lower median ejection fraction (27% vs 32%) compared with patients receiving ACEIs/ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36125061", "sentence_id": "med:pmid:36125061:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Adult patients with HFrEF who received ARNIs, ACEIs, or ARBs between January 1, 2014, and November 30, 2020, were identified.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36125061", "sentence_id": "med:pmid:36125061:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>RESULTS:</b> Among 12,250 patients with HFrEF receiving ACEIs, ARBs, or ARNIs, 556 (4.54%) patients received ARNIs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36125514", "sentence_id": "med:pmid:36125514:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan can be considered in initial treatment, even for patients in whom no previous treatment with an angiotensin converting enzyme inhibitor has been given.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36128010", "sentence_id": "med:pmid:36128010:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no significant difference between the doses of BB, ACEI, ARB, MRA, or ARNI among HFrEF patients on digoxin compared to those that were not.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36128010", "sentence_id": "med:pmid:36128010:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A bivariate analysis was performed to compare patients on digoxin with patients not on digoxin in terms of ability to progress the dosing of BB, ACEI, MRA, ARB, or ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36128010", "sentence_id": "med:pmid:36128010:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no significant difference between the two groups in terms of patients receiving higher doses of BB (P = 0.235), ACEI/ARB (P = 0.903), MRA (P = 0.331), or ARNI (P = 0.717).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36132549", "sentence_id": "med:pmid:36132549:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, HFpEF patients that underwent ARNI treatment achieved better outcomes than did patients that underwent ACEI treatment.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36133814", "sentence_id": "med:pmid:36133814:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan has been commonly compared to enalapril in cost effectiveness analysis and has been found to be similar to that of SGLT2i but was not considered a cost-effective treatment for heart failure with reduced ejection fraction in Thailand and Singapore with the current economic evaluation evidences.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36196235", "sentence_id": "med:pmid:36196235:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no significant reduction in the VT, VF, AF, or SVT incidence rate in the ARNI group compared to the ACEI/ARB group.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36196235", "sentence_id": "med:pmid:36196235:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 18,548 patients from all studies were included, with 9,328 patients in the ARNI arm and 9,220 patients in the angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) arm, with a median follow-up time of 15 months.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36196235", "sentence_id": "med:pmid:36196235:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was a significant reduction in the composite outcomes of SCD and ventricular arrhythmias in patients treated with ARNIs compared to those treated with ACEIs/ARBs (OR, 0.71; 95% confidence interval, 0.54-0.93; <i>P</i> = .01; I<sup>2</sup> = 17%; <i>P</i> = .29).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36252108", "sentence_id": "med:pmid:36252108:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Achievement of \u226550% target dose was low (beta blocker 45.9%, ACE inhibitor/angiotensin receptor blocker 31.6%, ARNI 19.0%) and for ACE inhibitor/angiotensin receptor blocker/ARNI, decreased over time.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36266969", "sentence_id": "med:pmid:36266969:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Within the RASi group, persistence was higher for ARNI than for ACEI and ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.500723+00:00"}
{"doc_id": "med:pmid:36304540", "sentence_id": "med:pmid:36304540:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In terms of the incidence of adverse reactions, the incidence of cough in ARNI was lower than that in ACEI/ARB group [RR = 0.69, 95%CI(0.60, 0.80), <i>P</i> < 0.00001], but the incidence of hypotension was higher [RR = 1.29, 95%CI(1.18, 1.41), <i>P</i> < 0.00001], and the adverse reactions of hyperkalemia, angioedema and renal insufficiency were not increased (<i>P</i> > 0.05).", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36304540", "sentence_id": "med:pmid:36304540:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEI/ARB, the use of ARNI can further reduce the total incidence of adverse cardiovascular events [RR = 0.72, 95%CI(0.62, 0.84), <i>P</i><0.0001] and the rate of HF rehospitalization [RR = 0.73, 95%CI(0.61, 0.86), <i>P</i> = 0.0002] in patients with acute myocardial infarction and heart failure; there was no significant difference in the incidence of cardiac death, recurrence of myocardial infarction, and malignant arrhythmia between the experimental group and the control group (<i>P</i> > 0.05).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36333668", "sentence_id": "med:pmid:36333668:sec:conclusion:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The short-term effect of ARNI treatment on the cardiac function of patients with STEMI and reduced LVEF after PPCI is not superior to that of ACEI treatment.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36333668", "sentence_id": "med:pmid:36333668:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After PSM, the study cohort consisted of 81 patients in the ARNI group and 123 in the ACEI group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36348348", "sentence_id": "med:pmid:36348348:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No treatments were effective in reducing mortality, but ARNIs, ACEIs or SGLT2 inhibitors reduced HF hospitalizations and only SGLT2 inhibitors reduced WHF events for patients with HFpEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36348348", "sentence_id": "med:pmid:36348348:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with placebo, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly reduced HF hospitalizations [odds ratio (OR)\u2009=\u20090.64, (95% confidence interval (95%CI 0.43\u2009-\u20090.96), OR\u2009=\u20090.73, (95%CI 0.61\u2009-\u20090.86), and OR\u2009=\u20090.74, (95%CI 0.66\u2009-\u20090.83), respectively] without heterogeneity among studies.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36353496", "sentence_id": "med:pmid:36353496:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI has a higher total effective rate (RR: 1.15, 95%CI: 1.08-1.21), Kansas City cardiomyopathy questionnaire (WMD: 4.13, 95%CI: 3.46-4.81), and 6-Minute Walk Test (WMD: 51.35, 95%CI: 26.99-75.71) compared with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36353496", "sentence_id": "med:pmid:36353496:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, long-term clinical studies with large samples are still needed to further explore the efficacy and safety of ARNI compared with ACEI or ARB in the HFmrEF population.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36440034", "sentence_id": "med:pmid:36440034:sec:methods:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among those 247 patients with MHD, 211 patients were already in treatment with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) before being treated with sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36440034", "sentence_id": "med:pmid:36440034:sec:methods:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We also performed an analysis to compare the differences between the 211 patients who had previously received ACEi/ARB treatment and the 36 patients who were sacubitril/valsartan naive.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36440034", "sentence_id": "med:pmid:36440034:sec:results:sent:16", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 211 patients who were already in treatment with ACEi/ARB and 36 patients who were sacubitril/valsartan naive, the improvement of cardiac function demonstrated by clinical outcomes and echocardiographic parameters were similar to the previous one of the 247 MHD patients with HFpEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovascular (CV)-related mortality and hospitalizations in heart failure (HF) with reduced or mildly reduced ejection fraction (EF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Eligible ARNI:ACEi/ARB patients (n\u2009=\u20097275:24,604) had a left ventricular EF\u2009<\u200950%.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Mortality and hospitalizations with ARNI (\u2264\u20093\u00a0months pre-/post-1 April 2016 index [SwedeHF]; n\u2009=\u20091506) versus ACEi/ARB (\u2264\u20093\u00a0months post-index; n\u2009=\u200917,108) were assessed using propensity score matching (1:1 ratio) with clinical variables, and sensitivity analysis (1:2/1:3 with, and 1:2 without clinical variables).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI induced a 23% reduction in all-cause mortality versus ACEi/ARB (1:1 hazard ratio [HR; 95% confidence interval\u00a0(CI)]: 0.77 [0.63-0.95], p\u2009=\u20090.013), and a non-significant 23% relative risk reduction in CV-related mortality (0.77 [0.54-1.09], p\u2009=\u20090.13), but no difference in all-cause or CV-related hospitalization (1.02 [0.91-1.13]; p\u2009=\u20090.76; 1.01 [0.91-1.15]; p\u2009=\u20090.84, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses confirmed all-cause mortality was reduced for ARNI versus ACEi/ARB (HR\u00a00.90 [95% CI 0.82-0.99], p\u2009=\u20090.026), but not CV-related mortality (HR\u00a01.04 [95% CI 0.89-1.22], p\u2009=\u20090.63).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36443599", "sentence_id": "med:pmid:36443599:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may have the potential to improve HRQoL in heart failure patients with reduced ejection fraction compared with ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hypotension is the most common adverse event with sacubitril/valsartan compared with ACEI/ARB.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Data on the effects of sacubitril/valsartan compared with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) on health-related quality of life (HRQoL) are limited.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To evaluate the comparative effects between sacubitril/valsartan and ACEI/ARB on HRQoL, a systematic review and meta-analysis were performed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PubMed, EMBASE, Web of Science, and ClinicalTrials.gov were searched from inception to March 2, 2022 for randomized controlled trials that compared the HRQoL scores, including Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), or Medical Outcomes Study Short-Form Health Survey 12 or 36 (SF-12/36), between sacubitril/valsartan and ACEI/ARB.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The KCCQ overall summary score and its subscales were significantly higher in sacubitril/valsartan compared with ACEI/ARB in heart failure patients with reduced ejection fraction, but were similar in heart failure patients with preserved ejection fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan conferred similar HRQoL scores in MLHFQ and SF-12/36 to ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The most frequently reported adverse event for sacubitril/valsartan is hypotension and the risk is higher than for ACEI/ARB.", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36475871", "sentence_id": "med:pmid:36475871:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36516938", "sentence_id": "med:pmid:36516938:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The use of ARNI was associated with significant reduction in blood pressure as compared to the ACEI/ARB group overall and across the eGFR spectrum, including in advanced chronic kidney disease.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36516938", "sentence_id": "med:pmid:36516938:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We assessed patterns of systolic and diastolic blood pressure among those started on ARNI or ACEI/ARB over 6 months, overall and across estimated glomerular filtration rate (eGFR).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36516938", "sentence_id": "med:pmid:36516938:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There were 13,781 individuals treated with an ACEI or ARB and 2589 individuals treated with an ARNI prescription.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36516938", "sentence_id": "med:pmid:36516938:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After propensity score matching, 839 patients were matched in each of the ARNI and ACEI/ARB groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36516938", "sentence_id": "med:pmid:36516938:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the ARNI group experienced greater systolic blood pressure reduction at month 3 (-5.2 mmHg vs -2.2 mmHg, ARNI vs ACEI/ARB; P < 0.001), and month 6 (-4.7 mmHg vs -1.85 mmHg, ARNI vs ACEI/ARB; P < 0.001).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36527023", "sentence_id": "med:pmid:36527023:sec:conclusion:sent:17", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI/ARB also had a beneficial effect but the effect was weaker than that of sacubitril/valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36527023", "sentence_id": "med:pmid:36527023:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) therapies were reported to affect glycaemic control and the development of diabetes mellitus (DM), but the findings are inconsistent.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36527023", "sentence_id": "med:pmid:36527023:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEI/ARB, sacubitril/valsartan treatment significantly increased the risk of hypoglycaemia among patients with HF (RR 1.85, 95% CI 1.12-3.06, p = 0.02) and HFpEF (RR 3.59, 95% CI 1.51-8.55, p = 0.004).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36530836", "sentence_id": "med:pmid:36530836:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b><i>Background:</i></b> Post hoc analysis of the PARADIGM-HF trial showed that sacubitril/valsartan (S/V) was more effective than enalapril in lowering HbA1c in patients with heart failure and diabetes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36601956", "sentence_id": "med:pmid:36601956:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study aimed to evaluate the pharmacokinetics and pharmacodynamics of single doses of sacubitril/valsartan (Part 1), and the efficacy and safety of sacubitril/valsartan versus enalapril administered twice daily for 52 weeks (Part 2) in pediatric patients with HF due to left ventricular systolic dysfunction with biventricular heart physiology.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36609948", "sentence_id": "med:pmid:36609948:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan had a lower all-cause mortality compared to ACEI/ARB in symptomatic HFrEF patients with CKD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36609948", "sentence_id": "med:pmid:36609948:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The differential effect of sacubitril/valsartan and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs) on the clinical and renal outcomes in patients with HFrEF and chronic kidney disease (CKD) remains unknown.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36609948", "sentence_id": "med:pmid:36609948:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After propensity score matching, the clinical and renal outcomes did not differ between the sacubitril/valsartan and ACEI/ARB groups in patients without CKD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36609948", "sentence_id": "med:pmid:36609948:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with CKD, the ACEI/ARB group had a significantly higher incidence of all-cause mortality than the sacubitril/valsartan group (14.89% vs. 10.50%; hazard ratio 1.46; 95% confidence interval 1.06-2.00; p = 0.02), and the incidence of AKI, HF hospitalization, and CV mortality did not differ between the two groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36614899", "sentence_id": "med:pmid:36614899:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Approximately 70% of patients received ACEi/ARBs/ARNi, 80% of patients received \u03b2-blockers, and 20% received MRAs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36633029", "sentence_id": "med:pmid:36633029:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The treatment of HFrEF consists of four pillars, the application of which leads to symptom reduction and better survival: (1) angiotensin converting enzyme inhibitor (ACE-i) or angiotensin receptor-neprilysin inhibitor (ARNI), (2) \u03b2-blocker, (3) mineralocorticoid receptor antagonist (MRA) and (4) sodium-glucose co-transporter 2 (SGLT2) inhibitor.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36660017", "sentence_id": "med:pmid:36660017:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This manuscript reviews the current therapeutic algorithm with a special focus on the therapeutic value of adding an MRA (still underused in both clinical trials and real world), changing an ACEi/ARB for an ARNi and incorporating an SGLT2i in patients with HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36685156", "sentence_id": "med:pmid:36685156:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor neprilysin inhibition (ARNI) is superior to enalapril in reducing the risk of cardiovascular death and heart failure hospitalization (HFH).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36713022", "sentence_id": "med:pmid:36713022:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At 120 days, 70% received \u226550% MTD ACEI/ARB/ARNI (<i>P</i>\u2009=\u20090.110) with % MTD increased to 64.4\u2009\u00b1\u200933.5% (<i>P</i>\u2009=\u20090.060).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36769667", "sentence_id": "med:pmid:36769667:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Current guidelines indicate to start therapy with angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors (ACEi/ARNI), beta blockers (BB), mineralocorticoid receptor antagonists (MRAs) and sodium glucose cotransporter 2 inhibitors (SGLT2i) to reduce the risk of death and hospitalization due to HF.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36769667", "sentence_id": "med:pmid:36769667:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Some authors suggest starting with SGLT2i and BB, others with ACEi or ARNI, while one of the most recent approach proposes to start with all four drugs together at low doses.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36808581", "sentence_id": "med:pmid:36808581:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan (an Angiotensin receptor-neprilysin inhibitor-ARNI) is one of the cornerstones in the management of patients with heart failure with reduced ejection fraction (HFrEF) having demonstrated significant reductions in both mortality and hospitalisations as compared with enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36808581", "sentence_id": "med:pmid:36808581:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In Argentina the cost-per quality adjusted life-year (QALY) gained for sacubitril/valsartan versus enalapril was 391,158 ARS and 376,665 ARS for a social security and a private payer, respectively, at a 30- year horizon.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36812948", "sentence_id": "med:pmid:36812948:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In sequential run-in phases, patients were titrated to enalapril 10\u00a0mg twice daily and then sacubitril/valsartan 97\u00a0mg/103\u00a0mg twice daily (in PARADIGM-HF) or valsartan 80\u00a0mg twice daily and then sacubitril/valsartan 49\u00a0mg/51\u00a0mg twice daily (in PARAGON-HF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36818914", "sentence_id": "med:pmid:36818914:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The putative ARNi-induced pro-arteriogenic effects were further investigated and compared with an angiotensin-converting enzyme inhibitor (ACEi).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.516751+00:00"}
{"doc_id": "med:pmid:36852608", "sentence_id": "med:pmid:36852608:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with HFrEF or recovered HFrEF, fundamental treatments were prescribed in 86% for angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or angiotensin receptor neprilysin inhibitor (ARNI), in 82% for beta-blocker, in 38% for mineralocorticoid receptor antagonist (MRA), and in 12% for sodium-glucose co-transporter-2 inhibitor (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.532882+00:00"}
{"doc_id": "med:pmid:36852608", "sentence_id": "med:pmid:36852608:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with HFmrEF or HFpEF, an ACEI, ARB, or ARNI was prescribed in 67%, beta-blocker in 67%, MRA in 22%, and SGLT2i in 7.4% with significantly lower probability of treatment compared to patients with HFrEF or recovered HFrEF [OR point estimates 0.33 to 0.57, all P-values\u00a0<\u00a00.05].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.532882+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although sacubitril/valsartan reduces mortality compared to ACEIs/ARBs in HF patients, they do not reduce AF risk compared to these drugs.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.532882+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan reduces all-cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.532882+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 284 AF events were reported in the sacubitril/valsartan group compared to 256 AF events in ACEIs/ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.534024+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients on sacubitril/valsartan were as likely as patients on ACEIs/ARBs to develop AF (pooled odds ratio [OR]\u2009=\u20091.091, 95% confidence interval [CI]\u2009=\u20090.917-1.298, p\u2009=\u2009.324).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.534024+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Six atrial flutter (AFl) events were reported in six trials; 48 out of 9165 patients in the sacubitril/valsartan group developed AFl compared to 46 out of 8759 in ACEi/ARBs group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.534024+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Finally, sacubitril/valsartan did not reduce the risk of atrial arrhythmias (AF\u2009+\u2009AFl) compared to ACEi/ARBs (pooled OR\u2009=\u20091.081, 95% CI\u2009=\u20090.922-1.269, p\u2009=\u2009.337).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.535014+00:00"}
{"doc_id": "med:pmid:36871177", "sentence_id": "med:pmid:36871177:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 11 trials including 11,458 patients on sacubitril/valsartan and 10,128 patients on ACEI/ARBs were identified.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.535014+00:00"}
{"doc_id": "med:pmid:36896801", "sentence_id": "med:pmid:36896801:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In HF hospitalizations, the impact of the pharmacological therapies was more notorious, and ARNi reduced in 40% the risk of HF hospitalizations (HR 0.60, 95% CI 0.39-0.92), SGLT2i in 26% (HR 0.74, 95% CI 0.59-0.93) and renin-angiotensin system inhibition (RASi) with ARB and ACEi in 28% (HR 0.72, 95% CI 0.53-0.98).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.535014+00:00"}
{"doc_id": "med:pmid:36918781", "sentence_id": "med:pmid:36918781:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean overall percentage of reported ACEI, ARB, MRA, and ARNI use, and the proportion of trials that included patients with advanced CKD grades 4-5 (estimated glomerular filtration rate (eGFR) <15-30 ml/min/1.73m<sup>2</sup>) were recorded per year.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.536014+00:00"}
{"doc_id": "med:pmid:36927423", "sentence_id": "med:pmid:36927423:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan is an established and effective therapy in HFrEF patients and should be considered as a replacement for angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.536014+00:00"}
{"doc_id": "med:pmid:36942494", "sentence_id": "med:pmid:36942494:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Seventeen patients switched from ACE inhibitors or ARBs to an ARNI (ARNI group), and the other 17 patients continued treatment with ACE inhibitors or ARBs (control group).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.536014+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan increased the ucGMP/BNP ratio, compared with enalapril, and the effect of sacubitril/valsartan on clinical outcomes was not modified by baseline ucGMP/BNP ratio.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.536014+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with baseline, the ucGMP/BNP ratio at 1 month and 8 months after randomization was higher with sacubitril/valsartan than with enalapril: ratio of geometric mean ratios at 1 month, 1.38 (95% CI, 1.27-1.51) and 8 months, 1.32 (95% CI, 1.20-1.45), and this difference was consistent across tertiles of ucGMP/BNP ratio at baseline (<i>P</i><sub>interaction</sub>=0.19 and 0.91, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.537025+00:00"}
{"doc_id": "med:pmid:36943907", "sentence_id": "med:pmid:36943907:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The effect of sacubitril/valsartan, compared with enalapril, was consistent across tertiles of ucGMP/BNP ratio at baseline for all outcomes (<i>P</i><sub>interaction</sub> \u22650.31).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.537025+00:00"}
{"doc_id": "med:pmid:36944496", "sentence_id": "med:pmid:36944496:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.538025+00:00"}
{"doc_id": "med:pmid:37042870", "sentence_id": "med:pmid:37042870:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.538025+00:00"}
{"doc_id": "med:pmid:37043670", "sentence_id": "med:pmid:37043670:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results of this study show that sacubitril/valsartan can be used in patients with AMI instead of enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.538025+00:00"}
{"doc_id": "med:pmid:37051752", "sentence_id": "med:pmid:37051752:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "CKD-EPI creatinine-cystatin C equation (creatinine-cystatin) was compared to creatinine-only (creatinine) equation in a subpopulation of Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.538025+00:00"}
{"doc_id": "med:pmid:37062869", "sentence_id": "med:pmid:37062869:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Using two clinical trials in HF\u00a0-\u00a0the Prospective comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM-HF) and the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure trials (ATMOSPHERE)\u00a0-\u00a0we identified the 10 most common comorbidities and examined 45 possible pairs.", "sentiment_label": "NEU", "sentiment_score": -0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.539025+00:00"}
{"doc_id": "med:pmid:37066800", "sentence_id": "med:pmid:37066800:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI has demonstrated superior cardioprotective effects compared with renin-angiotensin system inhibitors (RAS-Is) in large clinical trials such as the PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.539025+00:00"}
{"doc_id": "med:pmid:37104912", "sentence_id": "med:pmid:37104912:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In 5 years, the total cost of treating patients with HFrEF with sacubitril/valsartan at current market coverage and annual growth conditions is \u20b115.430 billion, which is \u20b111.077 billion higher than fully treating with enalapril only.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.540025+00:00"}
{"doc_id": "med:pmid:37104912", "sentence_id": "med:pmid:37104912:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The total required additional investment with treatment of sacubitril/valsartan compared with the full enalapril arm are \u20b1407 million (at 30-day coverage), \u20b1800 million (at 60-day coverage), and \u20b11.181 billion (at 90-day coverage).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.540025+00:00"}
{"doc_id": "med:pmid:37115135", "sentence_id": "med:pmid:37115135:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beta-blockers were the most frequently tolerated GDMT (93.1%), followed by ACEIs/ARBs/ARNIs (68.5%), and then MRAs (55.0%).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.540025+00:00"}
{"doc_id": "med:pmid:37115135", "sentence_id": "med:pmid:37115135:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Goal doses were uncommonly achieved for beta-blockers (32.3%) and ACEIs/ARBs/ARNIs (10.2%) due to intolerances limiting titration.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.541025+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan is associated with better outcomes and may be cost-effective compared to enalapril for the management of HFrEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.541025+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To assess the cost-effectiveness of sacubitril/valsartan compared with enalapril in patients with heart failure with reduced ejection (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.541025+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "All relevant full economic evaluation studies of sacubitril/valsartan versus enalapril for the treatment of patients with HFrEF were identified using ad hoc search strategies.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.541025+00:00"}
{"doc_id": "med:pmid:37143752", "sentence_id": "med:pmid:37143752:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.541025+00:00"}
{"doc_id": "med:pmid:37195574", "sentence_id": "med:pmid:37195574:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The Embase, PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) that compared sacubitril/valsartan with ACEI/ARBs in patients with CKD whose estimated glomerular filtration rate (eGFR) was below 60\u00a0mL/min/1.73\u00a0m<sup>2</sup>.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.542025+00:00"}
{"doc_id": "med:pmid:37195574", "sentence_id": "med:pmid:37195574:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Subgroup analysis about eGFR demonstrated that with long follow-up, sacubitril/valsartan significantly decreased the number of patients with more than 50% reduction in eGFR compared with ACEI/ARBs (OR: 0.52, 95% CI 0.32-0.84, P\u2009=\u20090.008, I<sup>2</sup>\u2009=\u20099%).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.542025+00:00"}
{"doc_id": "med:pmid:37217135", "sentence_id": "med:pmid:37217135:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Notably, 32% of the patients with HFrEF and an eGFR <30\u00a0mL/min/1.73\u00a0m<sup>2</sup> received the combination of ACEI/ARB/ARNi+beta-blockers+MRA+SGLT2i.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.543025+00:00"}
{"doc_id": "med:pmid:37240819", "sentence_id": "med:pmid:37240819:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.543025+00:00"}
{"doc_id": "med:pmid:37278232", "sentence_id": "med:pmid:37278232:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We investigate the cost-effectiveness of sequentially adding the SGLT2i and ARNi to form quadruple therapy as compared with the previous standard of care with ACE inhibitor/mineralocorticoid receptor antagonist/beta blocker.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.543025+00:00"}
{"doc_id": "med:pmid:37313196", "sentence_id": "med:pmid:37313196:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan had better clinical, intermediate, and renal outcomes in HF in comparison to ACEI or ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.543025+00:00"}
{"doc_id": "med:pmid:37313196", "sentence_id": "med:pmid:37313196:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "of the study was to assess the benefits and harms of sacubitril/valsartan (S/V) compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) in patients with HF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.544025+00:00"}
{"doc_id": "med:pmid:37374004", "sentence_id": "med:pmid:37374004:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In current clinical practice, the majority of patients with reduced and mildly-reduced LVEF are treated by ACEI/ARB and beta-blockers early following ACS, whereas MRA is underutilized and the adoption of SGLT2I and ARNI is low.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.544025+00:00"}
{"doc_id": "med:pmid:37374004", "sentence_id": "med:pmid:37374004:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI/ARB/ARNI and beta-blockers were used by the majority of patients in both LVEF groups, though ARNI was prescribed to only 3.9% (LVEF \u2264 40%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.544025+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Irrespective of anemia status, sacubitril/valsartan compared with enalapril, decreased mortality and hospitalization.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.544025+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in\u00a0Heart Failure [PARADIGM-HF] trial; NCT01035255).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.545014+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients assigned to sacubitril/valsartan were less likely to develop anemia at 12\u00a0months (321 of 2,806 [11.4%]) compared with patients randomized to enalapril (440 of 2,824 [15.6%]) (OR: 0.70 [95%\u00a0CI: 0.60-0.81]; P\u00a0< 0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.545014+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan, compared with enalapril, decreased the risk of cardiovascular death or heart failure hospitalization similarly in patients with (HR: 0.84; 95%\u00a0CI: 0.71-1.00) and without anemia (HR: 0.78 [95%\u00a0CI: 0.71-0.87]; P value for interaction\u00a0=\u00a00.478).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.545014+00:00"}
{"doc_id": "med:pmid:37407154", "sentence_id": "med:pmid:37407154:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Between baseline and 12\u00a0months, hemoglobin decreased by 1.5 g/L (95%\u00a0CI: 1.2-1.7 g/L) with sacubitril/valsartan compared with 2.3 g/L (95%\u00a0CI: 2.0-2.6 g/L) with enalapril: mean difference 0.8 g/L (95%\u00a0CI: 0.5-1.2 g/L; P\u00a0< 0.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37416920", "sentence_id": "med:pmid:37416920:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We evaluated the predictive performance of machine learning algorithms to predict prescription of four types of medications for adults with HFrEF: angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE/ARB), angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta blocker (BB), or mineralocorticoid receptor antagonist (MRA).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37429446", "sentence_id": "med:pmid:37429446:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Method</h4> In this retrospective cohort study, we compared the temporal change in chamber function and heart failure indices between 35 patients that received ARNI for >6\u00a0months, and a propensity matched control group (n\u00a0=\u00a070) of patients that received angiotensin converting enzyme inhibitor or angiotensin-II receptor blocker (ACEI/ARB) within the same period.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37429446", "sentence_id": "med:pmid:37429446:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared to the ACEI/ARB group, the ARNI group had greater relative improvement in LV global longitudinal strain (GLS) (28% versus 11% increase from baseline, p\u00a0<\u00a00.001) and RV-GLS (11% versus 4% increase from baseline, p\u00a0<\u00a00.001), and greater relative improvement in New York Heart Association functional class (-14 versus -2% change from baseline, p\u00a0=\u00a00.006) and N-terminal pro-brain natriuretic peptide levels (-29% versus -13% change from baseline, p\u00a0<\u00a00.001).", "sentiment_label": "POS", "sentiment_score": 4.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37544137", "sentence_id": "med:pmid:37544137:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with angiotensin-converting enzyme inhibitors (ACEis).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37544137", "sentence_id": "med:pmid:37544137:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 3,572 patients with HFrEF and who are na\u00efve to RASi therapy, at discharge, 290 (8.1%) were prescribed sacubitril/valsartan and 1,390 (38.9%) were prescribed ACEis and angiotensin receptor blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37544137", "sentence_id": "med:pmid:37544137:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In a restricted comparison of patients discharged on sacubitril/valsartan versus ACEis and angiotensin receptor blockers, there were no significant differences in the outcomes.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37573615", "sentence_id": "med:pmid:37573615:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At last follow-up, 51.2% were on a BB, 35.4% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37573615", "sentence_id": "med:pmid:37573615:sec:abstract:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was no association with hospitalization or mortality for baseline or follow-up BB, ACEI/ARB/ARNI, or MRA use.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37573615", "sentence_id": "med:pmid:37573615:sec:abstract:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, BBs, ACEI/ARB/ARNIs, and MRAs may be safely used in this population.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37573615", "sentence_id": "med:pmid:37573615:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At time of cardiac amyloidosis diagnosis, 63.4% were on a BB, 51.2% were on an ACEI/ARB/ARNI, and 43.9% were on an MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37619492", "sentence_id": "med:pmid:37619492:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarction, stroke, angina pectoris, peripheral artery disease, and the composite end point in patients with HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37619492", "sentence_id": "med:pmid:37619492:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 8 randomized controlled trials were included, with 17,541 patients assigned to either the ARNI (8,764 patients) or ACEi/ARB (8,777 patients) groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37619492", "sentence_id": "med:pmid:37619492:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incidence of composite end point (risk ratio [RR] 1.03, 95% confidence interval [CI] 0.93 to 1.13, p\u00a0=\u00a00.63), myocardial infarction (RR 1.02, 95% CI 0.81 to 1.30, p\u00a0=\u00a00.85), angina pectoris (RR 0.96, 95% CI 0.80 to 1.17, p\u00a0=\u00a00.70), and stroke (RR 0.99, 95% CI 0.85 to 1.16, p\u00a0=\u00a00.93) were not statistically different between the ARNI and ACEi/ARB groups.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37635080", "sentence_id": "med:pmid:37635080:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARALLEL-HF study assessed the efficacy and safety of sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37635080", "sentence_id": "med:pmid:37635080:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At OLE baseline, higher concentrations of B-type natriuretic peptide (BNP) and urine cGMP, and lower concentrations of N-terminal pro B-type natriuretic peptide (NT-proBNP), were observed in the sacubitril/valsartan core group (patients who received sacubitril/valsartan in both the core and extension study) than in the enalapril core group (patients who received enalapril in the core study and were then transitioned to sacubitril/valsartan).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37640175", "sentence_id": "med:pmid:37640175:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "For patients with HF or EF \u2264 40%, OMT included BB, spironolactone, and either Angiotensin Converting Enzyme inhibitors (ACEi)/angiotensin receptor blockers or angiotensin receptor neprilysin inhibitor (ARNI).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37640175", "sentence_id": "med:pmid:37640175:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "For CAD patients with normal EF, OMT also included ACEi/ARB/ARNI if they also had diabetes type 2.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37646297", "sentence_id": "med:pmid:37646297:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Price, affordability, and access\u00a0were substantially improved in all countries by substituting ARNI for ACEi/ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37705397", "sentence_id": "med:pmid:37705397:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1\u00a0year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37705397", "sentence_id": "med:pmid:37705397:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1\u00a0year of undergoing index echocardiography.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37705397", "sentence_id": "med:pmid:37705397:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The effect of ARNI versus that of ACEIs/ARBs in each group was assessed from the time of categorizing into new groups using the composite event of all-cause mortality and HF hospitalization.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37705397", "sentence_id": "med:pmid:37705397:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P\u00a0=\u00a00.020) and those with persistent HFrEF (17.6% vs. 49.7%, P\u00a0<\u00a00.001).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37705397", "sentence_id": "med:pmid:37705397:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P\u00a0=\u00a00.001) or not (15.0% vs. 54.9%, P\u00a0<\u00a00.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37861303", "sentence_id": "med:pmid:37861303:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At discharge, 92 patients (56%) were prescribed \u03b2-blockers, 28 (17%) were prescribed an ACE inhibitor, ARB or ARNI, and 50 (30%) were prescribed loop diuretics.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37917889", "sentence_id": "med:pmid:37917889:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37917889", "sentence_id": "med:pmid:37917889:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Randomized controlled trials comparing sacubitril/valsartan to ACEIs or ARBs in HFpEF patients were included.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37917889", "sentence_id": "med:pmid:37917889:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan substantially reduced heart failure hospitalization rates compared to ACEIs and ARBs, according to a total of six studies involving 5,201 participants (Relative Risk, 0.78; 95% CI, 0.65 to 0.85; P = .001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933210", "sentence_id": "med:pmid:37933210:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with BB and ACEi/ARB/ARNI was associated with lower mortality/morbidity.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933210", "sentence_id": "med:pmid:37933210:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA-ESC criteria for advanced HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933210", "sentence_id": "med:pmid:37933210:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with BB and ACEi/ARB/ARNI were associated with a lower risk of death or HF hospitalizations (adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.48-0.84, and HR 0.74, 95% CI 0.58-0.95, respectively).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933369", "sentence_id": "med:pmid:37933369:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, the sacubitril/valsartan combination proved to be beneficial in significantly reducing the risk of major adverse cardiac events (MACE) (RR: 0.64 {0.48, 0.84}) and rehospitalizations (RR: 0.53 {0.39, 0.71}) as compared to ACEI post MI.", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933369", "sentence_id": "med:pmid:37933369:sec:abstract:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the sacubitril/valsartan combination has no difference in mortality and outcomes compared to ACEI, there is evidence that using it proves to be more beneficial post MI compared to ACEI and ARB\u00a0usage alone.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933369", "sentence_id": "med:pmid:37933369:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Six studies analyzed the sacubitril/valsartan\u00a0and ACEI combination.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933369", "sentence_id": "med:pmid:37933369:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The pooled analysis reported a significant increase in the risk of hypotension (relative risk {RR}: 1.29 {1.18, 1.41}) in the sacubitril/valsartan compared to the ACEI alone group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37933369", "sentence_id": "med:pmid:37933369:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In addition, a significant increase was observed in the left ventricle ejection fraction (LVEF) after using the sacubitril/valsartan combination compared to using ACEI alone (RR: 3.08 {2.68, 4.48}).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37940331", "sentence_id": "med:pmid:37940331:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The RCTs were included if comparing any single or combination of drugs, that is, ACE inhibitors (ACEI), angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), ivabradine (IVA), angiotensin receptor blocker/neprilysin inhibitors (ARNI) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), soluble guanylyl cyclase and omecamtiv mecarbil and reporting PCO.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37940331", "sentence_id": "med:pmid:37940331:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Our findings suggested that ACEI+BB+MRA+SGLT2i, BB+MRA+ARNI, and ACEI+BB+MRA+IVA had lower probability of PCOs than the conventional triple therapy (ACEI+BB+MRA).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37941691", "sentence_id": "med:pmid:37941691:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril for chronic heart failure (CHF) with reduced ejection fraction (EF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No significant difference was observed between sacubitril/valsartan and enalapril for the composite outcome of cardiovascular death and HF hospitalization across SBP tertiles (P-interaction=0.2682).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the P-interaction value was not significant (0.2106), a greater reduction in NT-proBNP with sacubitril/valsartan compared with enalapril was observed in patients with SBP >130 mmHg (P=0.0076).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:37989299", "sentence_id": "med:pmid:37989299:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The incidence of hypotension-related events and reduction or discontinuation of treatment due to hypotension-related events was higher in the lower SBP subgroup, and these events were more frequent in the sacubitril/valsartan than enalapril group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38032698", "sentence_id": "med:pmid:38032698:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38040431", "sentence_id": "med:pmid:38040431:sec:introduction:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "During the study period, 33\u2009606 (84%) patients had an active prescription of beta blocker, 32\u2009626 (82%) had ACEi/ARB/ARNI, 11\u2009611 (29%) MRA and 7472 (19%) SGLT2i.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38040431", "sentence_id": "med:pmid:38040431:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Participants</h4> Patients seen at a large health system in New York City (NYC), who were >18 years old with diagnosis of HF or reduced ejection fraction (<40%) since 2017, had at least one clinical encounter between 1 April 2021 and 31 October 2022 and active prescriptions for any of the four GDMTs (beta-blocker, ACEi/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i)) during the study period.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38047039", "sentence_id": "med:pmid:38047039:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The utilization rate of ACEI/ARB/ARNI, \u03b2-blocker were high in management group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Pooled analysis showed that the risk of all-cause mortality was higher in patients receiving enalapril compared to patients receiving sacubitril/valsartan (risk ratio [RR]: 0.57; 95% CI: 0.31 to 1.04).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Risk of cardiovascular mortality was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.75; 95% CI: 0.62 to 0.91).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The risk of cardiovascular hospitalization was significantly higher in the enalapril group compared to the sacubitril/valsartan group (RR: 0.76; 95% CI: 0.66 to 0.86).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, our meta-analysis of nine studies underscores the superior clinical performance of sacubitril/valsartan compared to enalapril in managing patients with heart failure.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38084196", "sentence_id": "med:pmid:38084196:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of Outcomes Between Sacubitril/Valsartan and Enalapril in Patients With Heart Failure: A Systematic Review and Meta-Analysis.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38279516", "sentence_id": "med:pmid:38279516:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increasing the proportion of patients receiving ARNI instead of angiotensin converting enzyme inhibitors as first-line treatment of HFrEF will lead to a considerable number of additional life years gained and prevented hospitalizations but with additional cost in terms of health care expenditure in Sweden and in the United Kingdom.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38330576", "sentence_id": "med:pmid:38330576:sec:conclusion:sent:18", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.546015+00:00"}
{"doc_id": "med:pmid:38330576", "sentence_id": "med:pmid:38330576:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:conclusion:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In CHF patients, the combination of LBBP with sacubitril/valsartan had a better therapeutic effect compared to LBBP with enalapril, with more effective improvement of the cardiopulmonary function, reduction of myocardial injury, and improvement in quality of life.", "sentiment_label": "POS", "sentiment_score": 5.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To assess the efficacy of left bundle branch pacing (LBBP) combined with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure (CHF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We divided the data into two treatment groups for the analysis: 71 patients received LBBP combined with sacubitril/valsartan treatment (sacubitril/valsartan group), and 67 received LBBP combined with enalapril treatment (enalapril group).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38356826", "sentence_id": "med:pmid:38356826:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38359813", "sentence_id": "med:pmid:38359813:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among those individuals, 88.9% were prescribed beta-blockers, 72.3% with ACEI/ARBs, 67.9% with MRAs, and 13.1% with ARNIs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38418004", "sentence_id": "med:pmid:38418004:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart\u00a0Failure Events After MI; NCT02924727).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38465175", "sentence_id": "med:pmid:38465175:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hence, we conducted this review and meta-analysis, by adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)\u00a0guidelines and aligned with European Society of Cardiology recommendations, to compare sacubitril/valsartan with traditional ACEI/ARB treatments for AMI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38508844", "sentence_id": "med:pmid:38508844:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart\u00a0Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38508844", "sentence_id": "med:pmid:38508844:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38513366", "sentence_id": "med:pmid:38513366:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beta-blockers, ACEi/ARB/ARNI, and SGLT2i were independently associated with a lower risk of all-cause mortality in patients with HFmrEF, specifically when applied as combined 'HF triple therapy'.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38513366", "sentence_id": "med:pmid:38513366:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with BB [27.0 vs. 35.0%; hazard ratio (HR) = 0.737; 95% confidence interval (CI) 0.617-0.881; P = 0.001], ACEi/ARB/ARNI (25.9 vs. 37.6%; HR = 0.612; 95% CI 0.517-0.725; P = 0.001), and SGLT2i (11.9 vs. 29.5%; HR = 0.441; 95% CI 0.236-0.824; P = 0.010) was associated with a lower risk of 30-month all-cause mortality, which was still demonstrated after multivariable adjustment and propensity score matching.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38513366", "sentence_id": "med:pmid:38513366:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Finally, the lowest risk of long-term all-cause mortality was observed in patients with combined use of BB, ACEi/ARB/ARNI, and SGLT2i (HR = 0.456; 95% CI 0.227-0.916; P = 0.027).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38639469", "sentence_id": "med:pmid:38639469:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The proportion of patients receiving \u226550% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI/ARB/ARNI, and 18% versus 22% for MRA.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38644253", "sentence_id": "med:pmid:38644253:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Multivariate Cox proportional hazard regression analysis showed that increased left ventricular end-diastolic diameter (<i>HR</i>=1.21, 95%<i>CI</i>: 1.01-1.44, <i>P</i>=0.042), moderate or severe mitral regurgitation (<i>HR</i>=1.71, 95%<i>CI</i>: 1.19-2.47, <i>P</i>=0.004), increased ln (N-terminal pro-B-type natriuretic peptide) (<i>HR</i>=1.30, 95%<i>CI</i>: 1.10-1.54, <i>P</i>=0.002) were independent risk factors for dverse cardiovascular events in DCM patients, and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI) treatment (<i>HR</i>=0.45, 95%<i>CI</i>: 0.26-0.78, <i>P</i>=0.004) was independent protective factor.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38644253", "sentence_id": "med:pmid:38644253:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Conclusion:</b> An increase in left ventricular end-diastolic diameter, moderate or severe mitral regurgitation, elevated N-terminal pro-B-type natriuretic peptide, and non use of ACEI/ARB/ARNI are independent predictors of cardiovascular events in DCM patients.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38663899", "sentence_id": "med:pmid:38663899:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We report a case in which bilateral renal artery revascularisation allowed the safe reintroduction of enalapril (and subsequently sacubitril valsartan) in a patient with severe left ventricular systolic dysfunction.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38764991", "sentence_id": "med:pmid:38764991:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Background:</b> The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to enalapril in patients with reduced ejection fraction (HFrEF).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38783593", "sentence_id": "med:pmid:38783593:sec:conclusion:sent:17", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beyond the well-established risk for hyperkalaemia, our preliminary results suggest a potentially negative impact of saltSubs on GDMT use, especially for ACEis/ARBs/ARNis in CHF management.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38783593", "sentence_id": "med:pmid:38783593:sec:results:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The under-prescription of ACEi/ARB/ARNi was found when patients had EF\u00a0<\u00a040% (P\u00a0=\u00a00.029) and/or EF\u00a0\u2265\u00a040% (P\u00a0=\u00a00.043).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:conclusion:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Adding SGLT-2i to ARNI/ACEI\u00a0+\u00a0BB\u00a0+\u00a0MRA is beneficial for reversing cardiac remodeling.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The new quadruple drug \"ARNI\u00a0+\u00a0BB\u00a0+\u00a0MRA\u00a0+\u00a0SGLT-2i\" is superior to the golden triangle \"ACEI\u00a0+\u00a0BB\u00a0+\u00a0MRA\" in improving LVEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), \u03b2-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) are the cornerstones in treating heart failure with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI\u00a0+\u00a0BB\u00a0+\u00a0MRA\u00a0+\u00a0SGLT-2i (5.83%, 95% CI: 0.53% to 11.14%) and ARNI\u00a0+\u00a0BB\u00a0+\u00a0MRA (3.83%, 95% CI: 0.72% to 6.90%) were superior to the traditional golden triangle ACEI\u00a0+\u00a0BB\u00a0+\u00a0MRA in improving LVEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38930091", "sentence_id": "med:pmid:38930091:sec:introduction:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After adjusting for age, gender, smoking, hemoglobin (Hgb), use of SGLT2is at admission, use of Angiotensin-Converting Enzyme Inhibitors (ACEI-Is)/Angiotensin Receptor Blockers (ARBs) at discharge and Sacubitril/Valsartan at discharge, the aforementioned result remained significant (HR = 0.38; 95% CI: 0.19-0.73; <i>p</i> = 0.004).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38938237", "sentence_id": "med:pmid:38938237:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan was associated with lower 3-year rates of neurocognitive disorders when compared to ACEI/ARBs in patients with HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38938237", "sentence_id": "med:pmid:38938237:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The purpose of this study was to compare 3-year cognitive outcomes in patients with HFrEF who receive sacubitril/valsartan vs angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38938237", "sentence_id": "med:pmid:38938237:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Retrospective cohort study of: 1) 11,313 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on sacubitril/valsartan between 1/1/2015 and 12/31/2019; and 2) 11,313 propensity matched patients receiving ACEI/ARB during that time.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38938237", "sentence_id": "med:pmid:38938237:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At 3\u00a0years, 858 patients on sacubitril/valsartan met the primary endpoint vs 1,209 on ACEI/ARB (3-year incidence: 10.7% vs 15.0%; HR: 0.69; 95%\u00a0CI: 0.63-0.75; <i>P</i>\u00a0<\u00a00.001), with consistently lower rates of cognitive decline (9.5% vs 13.3%; HR: 0.69; 95%\u00a0CI: 0.63-0.76; <i>P</i>\u00a0<\u00a00.001), dementia (3.4% vs 5.0%; HR: 0.65; 95%\u00a0CI: 0.57-0.77; <i>P</i>\u00a0<\u00a00.001), and Alzheimer's disease (0.6% vs 1.3%; HR: 0.48; 95%\u00a0CI: 0.35-0.66; <i>P</i>\u00a0<\u00a00.001) in the sacubitril/valsartan cohort.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:38938237", "sentence_id": "med:pmid:38938237:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Three-year mortality was 22.0% on sacubitril/valsartan vs 24.6% on ACEI/ARB (HR: 0.89; 95%\u00a0CI: 0.84-0.94; <i>P</i>\u00a0<\u00a00.001).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39020009", "sentence_id": "med:pmid:39020009:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To investigate the effect of angiotensin receptor neprilysin inhibitors (ARNIs) on the blood ketone body levels, 46 stable pre-heart failure (HF)/HF patients were studied, including 23 who switched from angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to ARNIs (ARNI group) and 23 who continued treatment with ACE inhibitors or ARBs (control group).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39033432", "sentence_id": "med:pmid:39033432:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Conclusion:</b> Our study showed that ARNI resulted in a greater improvement in heart failure than ACEIs/ARBs in patients with HFrEF and moderate-to-severe CKD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39033432", "sentence_id": "med:pmid:39033432:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We performed a retrospective study to compare the efficacy of ARNI with that of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with HFrEF and moderate-to-severe CKD.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39033432", "sentence_id": "med:pmid:39033432:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<b>Results:</b> Compared with the ACEI/ARB group, the ARNI group, with 90.77% (59/65) in the lower target dose group, showed a lower rate of death due to cardiovascular disease (6.6% vs 0.9% after IPTW) and a lower incidence of rehospitalization (46.5% vs 30.4% after IPTW).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39058824", "sentence_id": "med:pmid:39058824:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan for the treatment of HFrEF is associated with a significantly lower rate of all-cause readmission as well as HF readmissions compared to ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39058824", "sentence_id": "med:pmid:39058824:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Eligible patients were adults (\u226518 years old) with a confirmed diagnosis of HFrEF who were discharged on either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) in addition to the other recommended therapy for HFrEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39058824", "sentence_id": "med:pmid:39058824:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 398 patients were included in our analysis; 199 (50.0%) received sacubitril/valsartan (group 1), and 199 (50.0%) received ACEI/ARB (group 2).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39105079", "sentence_id": "med:pmid:39105079:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI has proven effective in treating HFrEF patients; however, significant benefits were not observed in these patients with ESRD undergoing dialysis compared with ACEI/ARB in this real-world cohort.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39105079", "sentence_id": "med:pmid:39105079:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This multi-institutional, retrospective study identified 349 HFrEF patients with ESRD on dialysis, who initiated either ARNI or ACEI/ARB therapy.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39105079", "sentence_id": "med:pmid:39105079:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The primary composite rate of HHF or mortality was 20.6 events per 100 patient-years in the ARNI group and 26.1 in the ACEI/ARB group; the adjusted hazard ratio was 0.98 (95% CI: 0.28-3.43, <i>P</i>\u2009=\u20090.97).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39110471", "sentence_id": "med:pmid:39110471:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials enrolled patients with pulmonary congestion and/or left ventricular dysfunction after AMI.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200\u00a0mg twice daily vs enalapril 10\u00a0mg twice daily added to standard of care treatment for HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:abstract:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC [PARACHUTE-HF]; NCT04023227).", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39111953", "sentence_id": "med:pmid:39111953:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39186181", "sentence_id": "med:pmid:39186181:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Since ARNI and SGLT2i were introduced to treat heart failure (HF), its therapeutic regimen has modernized from previous treatment with beta-blocker (BB) and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) with mineralocorticoid receptor antagonist (MRA) as added-on in HF with reduced ejection fraction (HFrEF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39210725", "sentence_id": "med:pmid:39210725:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Participants with chronic HF, New York Heart Association classes II through IV symptoms, and elevated natriuretic peptides were randomized to treatment with either sacubitril/valsartan or a renin-angiotensin system inhibitor (RASi)-enalapril in the PARADIGM-HF trial or valsartan in the PARAGON-HF trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39210725", "sentence_id": "med:pmid:39210725:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan vs RASi (enalapril or valsartan).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39220717", "sentence_id": "med:pmid:39220717:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In this overall cohort, prior to admission ACEI/ARB/ARNI (45.6\u00a0% vs 48.1\u00a0%, p\u00a0<\u00a00.0001) and BB (56.9\u00a0% vs 62.4\u00a0%, p\u00a0<\u00a00.0001) use was lower among admitted HFrEF patients during the pandemic when compared to the year prior.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39220717", "sentence_id": "med:pmid:39220717:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Rates of ACEI/ARB/ARNI, MRA, and triple therapy (ACE/ARB/ARNI + BB\u00a0+\u00a0MRA) prescription at discharge were higher during the pandemic compared to the year prior.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.562243+00:00"}
{"doc_id": "med:pmid:39260836", "sentence_id": "med:pmid:39260836:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan, a combination drug consisting of a neprilysin inhibitor and an angiotensin receptor blocker (ARB), has shown a greater improvement in the prognosis of HF than ACE inhibitors (ACEI) or ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39260836", "sentence_id": "med:pmid:39260836:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Recent studies have found that ACEI/ARB or sacubitril/valsartan can increase flow-mediated dilation (FMD) and reduce pulse wave velocity (PWV), which are independent predictors of cardiovascular events and HF prognosis.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39260836", "sentence_id": "med:pmid:39260836:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Methods and analysis</h4> Clinical randomised controlled trials investigating the effect of sacubitril/valsartan and/or ACEI/ARB on FMD and PWV in patients with HF will be searched in the relevant database, including PubMed, Web of Science, Embase, Cochrane Library and China's National Knowledge Infrastructure up to January 2024.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39260836", "sentence_id": "med:pmid:39260836:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparative effects of sacubitril/valsartan and ACEI/ARB on endothelial function and arterial stiffness in patients with heart failure: a protocol for systematic review and meta-analysis.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39262640", "sentence_id": "med:pmid:39262640:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In PARALLEL-HF, in which 223 patients with HF and reduced ejection fraction (HFrEF) were randomized to the angiotensin-receptor neprilysin inhibitor (sacubitril/valsartan) or enalapril, 97 (43%) received influenza vaccination.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39264627", "sentence_id": "med:pmid:39264627:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan treatment was associated with shorter time to the primary outcome compared with ACEI/ARB treatment (20 of 63 [31.7%] vs 38 of 117 [32.5%]; adjusted hazard ratio [aHR], 1.85; 95% CI, 1.05-3.23).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39264627", "sentence_id": "med:pmid:39264627:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan treatment was independently associated with shorter time to a 15% increase in eGFR (15 of 46 [32.6%] vs 46 of 83 [55.4%]; aHR, 2.13; 95% CI, 1.09-4.17) and kidney survival free from dialysis (11 of 23 [47.8%] vs 16 of 57 [28.1%]; aHR, 2.63; 95% CI, 1.15-5.88) compared with ACEI/ARB treatment.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39264627", "sentence_id": "med:pmid:39264627:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Exposures</h4> Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200\u202fmg twice daily or enalapril 10\u202fmg twice daily.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of 223 patients, 28.2\u202f% experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95\u202f% CI, 1.3-3.8; p\u202f=\u202f0.0027).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4\u202f% vs 6.9\u202f%, p\u202f=\u202f0.5957).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.", "sentiment_label": "NEG", "sentiment_score": -3.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39318024", "sentence_id": "med:pmid:39318024:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39319469", "sentence_id": "med:pmid:39319469:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 375 children (mean age, 8.1\u00b15.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The safety of sacubitril/valsartan vs enalapril was also maintained regardless of the occurrence of hypotension.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Discontinuation of randomized treatment was less common with sacubitril/valsartan vs enalapril in patients experiencing asymptomatic and symptomatic hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39320292", "sentence_id": "med:pmid:39320292:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, the effect of sacubitril/valsartan on the primary outcome was not diminished in patients experiencing hypotension compared to those who did not: the HR for sacubitril/valsartan vs enalapril was 0.80 (95% CI: 0.72-0.89) for no hypotension, 0.87 (95% CI: 0.70-1.08) for asymptomatic hypotension, and 0.51 (95% CI: 0.38-0.69) for symptomatic hypotension (P<sub>interaction</sub>\u00a0=\u00a00.01), and this was also true for cardiovascular and all-cause deaths.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39412629", "sentence_id": "med:pmid:39412629:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39439294", "sentence_id": "med:pmid:39439294:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF\u2009\u226440% (PARADIGM-HF) or LVEF \u226545% (PARAGON-HF).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39455534", "sentence_id": "med:pmid:39455534:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:methods:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39544776", "sentence_id": "med:pmid:39544776:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39544776", "sentence_id": "med:pmid:39544776:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39620289", "sentence_id": "med:pmid:39620289:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39620289", "sentence_id": "med:pmid:39620289:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While 52.6% of physicians considered angiotensin receptor-neprilysin inhibitor (ARNi) treatment the most effective medication for HF, 62.7% would initiate HF treatment with an angiotensin-converting enzyme inhibitor (ACEi) instead of ARNi due to reimbursement and cost issues.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39622578", "sentence_id": "med:pmid:39622578:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "HFrEF patients with symptomatic LVEF\u226435% despite ACE inhibitor/beta blocker/mineralocorticoid receptor antagonist therapy, and qualified for sacubitril/valsartan switchover were recruited to this single centre prospective study.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022).", "sentiment_label": "NEG", "sentiment_score": -2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39687932", "sentence_id": "med:pmid:39687932:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39720381", "sentence_id": "med:pmid:39720381:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (<i>p</i>=0.01).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (<i>p</i>=0.001).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.578298+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Paired <i>t</i>-test was used to compare the outcomes of ACEI and ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with <i>p</i><0.001).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39864551", "sentence_id": "med:pmid:39864551:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum\u00ae dataset in the United States.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This retrospective cohort study included adult patients with de novo HFrEF (diagnosed \u226430\u00a0days) with left ventricular ejection fraction (LVEF) \u226440% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P\u00a0<\u00a00.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P\u00a0<\u00a00.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P\u00a0=\u00a00.002).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among the 999 included patients, \u03b2-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and \u226550% target dose.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39970741", "sentence_id": "med:pmid:39970741:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs ACE Inhibitors or\u00a0ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6\u00a0months in patients with hematologic malignancies treated with BMT.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients treated with sacubitril/valsartan or enalapril for 6\u00a0months did not show a deterioration of LV GLS or LVEF (P\u00a0>\u00a00.05).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P\u00a0=\u00a00.044 and P\u00a0=\u00a00.011, respectively) at 6\u00a0months.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40091512", "sentence_id": "med:pmid:40091512:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40101251", "sentence_id": "med:pmid:40101251:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40115097", "sentence_id": "med:pmid:40115097:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and \u03b2-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Propensity score matching (1:1) was applied to balance ARNi and ACEi groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40283370", "sentence_id": "med:pmid:40283370:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:discussion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52\u00a0weeks.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs.", "sentiment_label": "NEU", "sentiment_score": 0.5, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40448468", "sentence_id": "med:pmid:40448468:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40450497", "sentence_id": "med:pmid:40450497:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study was conducted to evaluate the possible impact of ARNI therapy compared to ACEI on cardiac remodeling using echocardiographic parameters, including global longitudinal strain (GLS) in heart failure with reduced left ventricular ejection fraction (HFrEF) patients.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40470816", "sentence_id": "med:pmid:40470816:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.594300+00:00"}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We conducted a systematic review and meta-analysis of published studies assessing the use of ARNIs in ACHD patients with HF, comparing them to ACEIs/ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40540017", "sentence_id": "med:pmid:40540017:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40542996", "sentence_id": "med:pmid:40542996:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi\u2009+\u2009SGLT2i (2.2%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40660106", "sentence_id": "med:pmid:40660106:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40718065", "sentence_id": "med:pmid:40718065:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A high rate of ACEI/ARB/ARNI and BB use was observed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40755965", "sentence_id": "med:pmid:40755965:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40769236", "sentence_id": "med:pmid:40769236:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40835081", "sentence_id": "med:pmid:40835081:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40839760", "sentence_id": "med:pmid:40839760:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below \u20ac20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI significantly reduced MEE compared with ACEI/ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61\u2009\u00b1\u200940.81)\u2005kcal/min vs. (154.49\u2009\u00b1\u200947.58)\u2005kcal/min, <i>P</i>\u2009<\u20090.01].", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40908036", "sentence_id": "med:pmid:40908036:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study population was categorized into pts receiving ARNI and ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41079061", "sentence_id": "med:pmid:41079061:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i>\u2009=\u20090.002).", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41080832", "sentence_id": "med:pmid:41080832:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41084891", "sentence_id": "med:pmid:41084891:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 64 patients (22.3%) attained the 4\u2011pillar GDMT of SGLT2i, ARNI/ACEI/ARB, \u03b2\u2011blockers, and MRA at doses equal to or above 50% of the target dose.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41151613", "sentence_id": "med:pmid:41151613:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Since 2021, evidence\u2011based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological \"pillars\":\u202f\u03b2\u2011blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid\u2011receptor antagonists, and sodium-glucose co\u2011transporter\u20112 (SGLT\u20112) inhibitors.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69]).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:16", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99]).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41284794", "sentence_id": "med:pmid:41284794:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The last NICE guidelines in 2018 proposed as a second stage one or more of the following interventions delivered by a specialist: angiotensin receptor/neprilysin antagonist (ARNI) instead of ACE inhibitor, ivabradine if in sinus rhythm with a heart rate >70 bpm, a combined hydralazine and nitrate if the patient is of Afro-Caribbean origin, and/or digoxin.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No significant between-group differences were observed in drug utilization rate of \u03b2-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beta-blockers were discontinued less often than were ACEi/ARB/ARNI.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.609948+00:00"}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P\u200a=\u200a0.577 and P\u200a=\u200a0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P\u200a=\u200a0.575).", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 38 (22.0%) patients reached the level of treatment corresponding to \"SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses \u2265 50%\".", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%.", "sentiment_label": "POS", "sentiment_score": 4.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P\u2009<\u2009.001) for sacubitril/valsartan compared with enalapril.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.", "sentiment_label": "NEG", "sentiment_score": -1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41377094", "sentence_id": "med:pmid:41377094:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In a large-scale randomized controlled study of heart failure (HF), angiotensin receptor-neprilysin inhibitors (ARNI) reduced cardiovascular events compared to enalapril, but resulted in more symptomatic hypotension.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 166 patients treated with newly prescribed renin-angiotensin system inhibitor (75.7\u2009\u00b1\u200913.4 years, 57.2% men, and ejection fraction 39\u2009\u00b1\u200917%), 114 were treated with newly prescribed ARNI (ARNI group) and 52 were treated with newly prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers but without ARNI (ACEi/ARB group).", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The initial day of prescription was day 4 [2-6] for the ARNI group and day 3 [1-6] for the ACEi/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "med:pmid:41501364", "sentence_id": "med:pmid:41501364:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early changes in BP after ARNI initiation were comparable with those in the ACEi/ARB group.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.1101/2023.10.31.23297731", "sentence_id": "ppr:doi:10.1101/2023.10.31.23297731:sec:conclusion:sent:16", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Physicians\u2019 level of adherence to prescription and up-titration of GDMT was satisfactory for ACEI/ARNI/ARBs and B-blockers, however, it was poor for SGLT2is and MRAs.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.1101/2025.03.12.25323680", "sentence_id": "ppr:doi:10.1101/2025.03.12.25323680:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The combinations which resulted in the greatest improvement of quality of life were ARNi + BB + MRA + SGLT2i [MD 7.11 (95% CI -0.99-15.22)], which did not have a statistically significant effect, followed by ARNi + BB + SGLT2i [MD 5.33 (95% CI 0.40-10.25)], ACEi + BB + MRA+ SGLT2i [MD 5.32 (95% CI -2.63-13.26)], ACEi + BB + MRA + ivabradine [MD 5.24 (95% CI -3.07-13.55)].", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function.", "sentiment_label": "POS", "sentiment_score": 2.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study population was catego-rized into pts receiving ARNI and ACEI/ARB.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Median \u0394LVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Similarly median relative \u0394LVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047].", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p&amp;lt;0.0001) in ACEI/ARB subgroup.", "sentiment_label": "POS", "sentiment_score": 1.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.20944/preprints202509.0619.v1", "sentence_id": "ppr:doi:10.20944/preprints202509.0619.v1:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.21203/rs.3.rs-6768681/v1", "sentence_id": "ppr:doi:10.21203/rs.3.rs-6768681/v1:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While therapy with beta blockers and ACEI/ARB/ARNI was common within the cohort, only a third of the cohort was treated with SGLT2 inhibitors or mineralocorticoid receptor antagonists.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
{"doc_id": "ppr:doi:10.22541/au.166607824.44692296/v1", "sentence_id": "ppr:doi:10.22541/au.166607824.44692296/v1:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan was advantageous over ACEI in heart failure patients for further reduction of cardiovascular death or heart failure re-hospitalization.", "sentiment_label": "NEU", "sentiment_score": 0.0, "sentiment_model": "lexicon_v1", "sentiment_inference_ts": "2026-01-08T18:51:51.625816+00:00"}
